Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
18 January 2012
Ian Haydock
Please Login to read the full article.
18 January 2012
Ian Haydock
ian.haydock@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Denosumab filed for large but competitive osteoporosis indication in Japan
- AstraZeneca boosts oncology portfolio in Japan with Daiichi denosumab deal
- US FDA rejects Amgen's Xgeva in prostate cancer; more data needed
- New Japanese approvals include Xarelto for stroke prevention
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
- Merck BioVentures: where biosimilars make a difference
- DKSH highlights one-stop benefits as it builds Asia market expansion services
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
